ACCEL Lite: ACC.21 Late Breaker: The ATLANTIS Trial

The ATLANTIS trial will change the way antithrombotic treatments are chosen after successful transcatheter aortic valve implantation. In this interview, Roxana Mehran, MD, FACC; Jean-Philippe Collet, MD; and Zaid I. Almarzooq, MBBCh, discuss anti-xa oral anticoagulation after valve implantation for aortic stenosis.

Like what you hear? ACCEL Subscribers enjoy 20+ insider interviews like these every month, with CME/MOC credit and other exclusive benefits. Subscribe today for more, and check out what's new at

Clinical Topics: Anticoagulation Management, Arrhythmias and Clinical EP, Cardiac Surgery, Invasive Cardiovascular Angiography and Intervention, Valvular Heart Disease, Anticoagulation Management and Atrial Fibrillation, Atrial Fibrillation/Supraventricular Arrhythmias, Aortic Surgery, Cardiac Surgery and Arrhythmias, Cardiac Surgery and VHD, Interventions and Structural Heart Disease

Keywords: ACC Annual Scientific Session, ACC21, ACCELLite, Anticoagulants, Transcatheter Aortic Valve Replacement, Platelet Aggregation Inhibitors, Atrial Fibrillation, Aortic Valve Stenosis

< Back to Listings